What are the possible causes of muscle and joint pain in a 54-year-old woman with a positive antinuclear antibody (ANA) and low‑titer anti‑ribonucleoprotein (RNP) antibodies?

Differential Diagnosis: Connective Tissue Disease with Positive ANA and Low-Titer RNP Antibodies

In a 54-year-old woman with muscle and joint pain, positive ANA, and low-titer RNP antibodies, the most likely diagnoses are Mixed Connective Tissue Disease (MCTD), systemic lupus erythematosus (SLE) with myositis, or an overlap syndrome—with the specific diagnosis depending on the presence of additional clinical features including Raynaud's phenomenon, swollen hands, skin manifestations, and interstitial lung disease.

Primary Diagnostic Considerations

The combination of positive ANA with anti-RNP antibodies creates a specific clinical signature. Anti-RNP antibodies identify patients with a consistent set of features: arthritis, swollen hands, Raynaud's phenomenon, and myositis 1. This serologic profile occurs in several conditions:

1. Mixed Connective Tissue Disease (MCTD)

• Most characteristic when high-titer anti-U1-RNP antibodies are present 2
• Look specifically for: Raynaud's phenomenon, puffy/swollen hands, arthritis, and myositis 1
• Can present with isolated muscle involvement (even drop head syndrome) as the only manifestation 3
• Leukopenia supports this diagnosis 3

2. Anti-U1-RNP Positive Myositis

• Patients typically present younger (around 37 years) but can occur at any age 4
• 60% develop arthritis—significantly higher than dermatomyositis (18%) or immune-mediated necrotizing myopathy (6%) 4
• 80% eventually develop muscle weakness, though only 15% present with weakness initially 4
• Muscle biopsies often show necrotizing features (4 of 7 patients in one series) 4
• 45% develop interstitial lung disease 4

3. SLE with Myositis

• Anti-RNP antibodies occur in SLE patients, particularly those with muscle involvement 5
• Joint symptoms are typically the predominant feature 6
• Can cause severe joint deformities requiring surgical intervention 6

Critical Clinical Features to Assess

Immediately evaluate for:

• Raynaud's phenomenon (color changes in fingers/toes with cold exposure)
• Swollen hands or puffy fingers (not just joint swelling)
• Pattern of joint involvement: symmetrical polyarthritis vs. oligoarthritis of large joints
• Skin manifestations: DM-specific rashes (Gottron's papules, heliotrope rash) occur in 60% of anti-U1-RNP myositis 4
• Respiratory symptoms: dyspnea, cough suggesting interstitial lung disease
• True muscle weakness (difficulty rising from chair, lifting arms) vs. pain alone
• Sicca symptoms: dry eyes, dry mouth

Essential Laboratory Workup

Order immediately:

• Inflammatory markers: ESR and CRP (typically very elevated in inflammatory conditions)
• Creatine kinase (CK): distinguishes myositis (elevated) from polymyalgia-like syndrome (normal) 7
• Complete blood count: check for leukopenia (suggests MCTD) 3
• Specific autoantibodies:
  • Anti-Ro52/SSA (pericarditis and glomerulonephritis occur only with coexisting anti-Ro52 in anti-U1-RNP patients) 4
  • Anti-dsDNA, anti-Smith (for SLE)
  • Rheumatoid factor and anti-CCP (often positive in anti-U1-RNP myositis) 7
  • Anti-Jo-1 and other myositis-specific antibodies 2

Important caveat: Even with negative ANA by some methods, specific antibodies like anti-Jo-1, ribosomal P, or SS-A/Ro may be positive 2. If clinical suspicion is high, test for specific antibodies regardless of ANA result [2, @23@].

Imaging and Additional Studies

If muscle involvement suspected:

• MRI of affected muscles: shows increased intensity and edema in myositis 8
• EMG: demonstrates muscle fibrillations in myopathy 7
• Consider muscle biopsy if diagnosis unclear (may show necrotizing features) 4

If respiratory symptoms present:

• High-resolution chest CT: evaluate for interstitial lung disease (occurs in 45% of anti-U1-RNP myositis) 4
• Pulmonary function tests

If joint involvement prominent:

• Plain radiographs of affected joints to assess for erosions 7
• Ultrasound or MRI if clinical examination unclear 7

Unique Features of Anti-U1-RNP Disease

Distinguishing characteristics:

• Pericarditis (40%) and glomerulonephritis (25%) are uniquely found in anti-U1-RNP myositis but only in those with coexisting anti-Ro52 antibodies 4
• No cancer-associated myositis reported in anti-U1-RNP patients 4
• Better prognosis: no deaths reported during study periods 4
• More common in Black patients (60% in one series) 4

Common Pitfalls to Avoid

1. Low-titer RNP antibodies are less specific: High titers are more characteristic of MCTD 2. Low titers may occur in other conditions or even healthy individuals.

2. Don't assume all muscle pain is myositis: Polymyalgia-like syndrome has pain without true weakness and normal CK levels 7.

3. Joint pain doesn't always mean arthritis: Examine for objective synovitis (swelling, warmth, effusion), not just arthralgia 7.

4. ANA patterns matter: Request the specific pattern (speckled, homogeneous, nucleolar) as this provides diagnostic clues 2.

5. Serologies evolve over time: A patient may develop new autoantibodies during disease course 9.

Management Approach

Rheumatology referral is essential for definitive diagnosis and treatment planning. The specific therapy depends on which organs are involved and disease severity, but typically includes:

• Corticosteroids (prednisone 20-40 mg/day depending on severity) 7
• Disease-modifying antirheumatic drugs (methotrexate, azathioprine, mycophenolate) for steroid-sparing 7
• Biologic agents (rituximab, tocilizumab) for refractory cases 7

The presence of anti-U1-RNP antibodies with muscle and joint pain should prompt urgent evaluation for systemic connective tissue disease, as early diagnosis and treatment significantly impact quality of life and prevent organ damage.